Allostery Investments LP Takes $4.77 Million Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Allostery Investments LP bought a new stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 284,517 shares of the company's stock, valued at approximately $4,766,000. Centessa Pharmaceuticals comprises approximately 4.9% of Allostery Investments LP's investment portfolio, making the stock its 2nd largest position. Allostery Investments LP owned about 0.22% of Centessa Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its stake in Centessa Pharmaceuticals by 14.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company's stock valued at $89,854,000 after acquiring an additional 685,371 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of Centessa Pharmaceuticals by 22.0% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company's stock valued at $85,744,000 after buying an additional 924,027 shares during the period. Franklin Resources Inc. grew its stake in shares of Centessa Pharmaceuticals by 0.3% during the 4th quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company's stock worth $38,668,000 after acquiring an additional 6,000 shares during the period. Foresite Capital Management VI LLC purchased a new stake in Centessa Pharmaceuticals in the 4th quarter worth about $20,994,000. Finally, Affinity Asset Advisors LLC raised its stake in Centessa Pharmaceuticals by 13.5% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,095,924 shares of the company's stock valued at $18,357,000 after acquiring an additional 130,312 shares during the period. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, General Counsel Iqbal J. Hussain sold 2,080 shares of the firm's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $14.01, for a total transaction of $29,140.80. Following the completion of the sale, the general counsel now directly owns 105,386 shares in the company, valued at approximately $1,476,457.86. This trade represents a 1.94 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $15.93, for a total transaction of $876,150.00. Following the completion of the transaction, the chief executive officer now owns 331,017 shares in the company, valued at approximately $5,273,100.81. This represents a 14.25 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 202,353 shares of company stock worth $3,286,478 in the last 90 days. Insiders own 11.59% of the company's stock.

Centessa Pharmaceuticals Trading Up 1.6 %

Shares of Centessa Pharmaceuticals stock traded up $0.19 during trading on Wednesday, reaching $12.20. The company's stock had a trading volume of 197,787 shares, compared to its average volume of 617,996. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a 52-week low of $7.75 and a 52-week high of $19.09. The firm's 50-day moving average is $14.07 and its two-hundred day moving average is $15.74. The company has a market cap of $1.62 billion, a price-to-earnings ratio of -7.97 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.04. On average, sell-side analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on CNTA. TD Cowen began coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a "buy" rating for the company. Guggenheim reiterated a "buy" rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Piper Sandler started coverage on Centessa Pharmaceuticals in a research note on Monday, March 31st. They issued an "overweight" rating and a $38.00 target price for the company. Finally, Morgan Stanley reissued an "overweight" rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $27.71.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.